Incretins and their role in the management of diabetes
Authors:
- Juan P FriasJFJuan P Frias
- Steven V EdelmanSESteven V Edelman
- 1 August 2007
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Endocrinology, Diabetes and Obesity
- Vol. 14 (4) , 269-276
Abstract
To review data from clinical trials of incretin mimetics in patients with type 2 diabetes. Incretin mimetics are a new class of antidiabetic medication that mimic the actions of the hormone glucagon-like peptide-1. They exhibit several properties, including glucose-dependent stimulation of insulin secretion, suppression of glucagon secretion, slowing of gastric emptying and induction of satiety, which result in improvements in glycemic control with weight loss in patients with type 2 diabetes. Recent 2-year data with exenatide, the only commercially available incretin mimetic, have demonstrated long-term sustained reductions in hemoglobin A1c with progressive weight loss. Glycemic and weight benefits were also recently reported in a 15-week study assessing once-weekly administration of long-acting release exenatide, a formulation currently in phase 3 of clinical development. Once-daily administration of liraglutide, also in phase 3 of development, has recently been shown to improve glycemic and weigh control as monotherapy, and in combination with metformin. The most common side effects of incretin mimetics are gastrointestinal in nature, particularly nausea. The ability of incretin mimetics to improve glycemic control and reduce body weight is a unique property that fills an important void in the treatment of patients with type 2 diabetes.Keywords
This publication has 54 references indexed in Scilit:
- Effects of Once-Weekly Dosing of a Long-Acting Release Formulation of Exenatide on Glucose Control and Body Weight in Subjects With Type 2 DiabetesDiabetes Care, 2007
- The role of gut hormones in glucose homeostasisJournal of Clinical Investigation, 2007
- A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority studyDiabetologia, 2006
- Pramlintide in the treatment of diabetesInternational Journal Of Clinical Practice, 2006
- Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metforminDiabetes/Metabolism Research and Reviews, 2006
- Effects of liraglutide (NN2211), a long‐acting GLP‐1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetesDiabetic Medicine, 2005
- The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits β-cell apoptosis in vitroBiochemical and Biophysical Research Communications, 2005
- Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Sulfonylurea-Treated Patients With Type 2 DiabetesDiabetes Care, 2004
- Glucagon-like Peptide-1 Receptor Signaling Modulates β Cell ApoptosisJournal of Biological Chemistry, 2003
- Amylinʼs physiology and its role in diabetesCurrent Opinion in Endocrinology, Diabetes and Obesity, 1997